Compare Dropbox Inc (DBX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M). The key difference: Dropbox Inc is far larger — about 9.7× Ginkgo Bioworks Holdings Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DBX | DNA | |
|---|---|---|
Market Cap | $7.42B | $763.64M |
Volume | 3,061,580 | 3,204,177 |
Sector | Technology | Health |
52-Week High | $37.74 | $15.83 |
52-Week Low | $22.06 | $5.48 |
Typical Hold Time | 97 Days | 7 Days |
Enterprise Value | $10.29B | $865.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% amid bearish technical signals and mixed analyst sentiment. The company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. However, negative shareholder equity and recent insider selling create headwinds. Technical indicators show bearish momentum with support at $32 and resistance at $34.
Outlook remains cautious despite solid fundamentals. The stock faces valuation concerns with a P/E of 18.86 and mixed analyst ratings (37.5% buy, 31.25% hold/sell each). Key risks include stagnant revenue growth, high debt levels, and competitive pressures in cloud storage. The consensus price target of $26.83 suggests potential downside from current levels.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
